Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans

Journal of Clinical Psychopharmacology

Volumn 21, Issue 2, 2001, Pages 175-184

  Lessard, Étienne ^a,b   Yessine, Marie Andrée ^b   Hamelin, Bettina A ^a,b   Gauvin, Caroline ^a,b   Labbé, Line ^a,b   O'Hara, Gilles ^a,b   LeBlanc, Jacynthe ^c   Turgeon, Jacques ^a,b,d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CYTOCHROME P450 2D6; DIPHENHYDRAMINE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; VENLAFAXINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC INHIBITION; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DIPHENHYDRAMINE; DRUG INTERACTIONS; ENZYME INHIBITORS; GENOTYPE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; PHENOTYPE;

EID: 0035106383     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200104000-00009     Document Type: Article

References (47)

1. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
2. Overall safety profile of venlafaxine
3. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine
4. Effect of venlafaxine on the pharmacokinetics of alprazolam
5. Effect of venlafaxine on the pharmacokinetics of terfenadine
6. Drug-drug interactions involving antidepressants: Focus on venlafaxine
7. Evidence that venlafaxine does not inhibit CYP1A2 as measured in vivo by the metabolism of caffeine
8. Venlafaxine: A review of its pharmacology and therapeutic potential in depression
9. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man
10. The disposition of venlafaxine enantiomers in dogs, rats, and human receiving venlafaxine
11. Biochemical, neurophysiological, and behavioral effects of Wy-45,030, an ethyl cyclohexanol derivative
12. A prefatory investigation of the metabolic disposition of Wy-45.030 in man
13. An ascending single-dose tolerance study of Wy-45.030 a bicyclic antidepressant in healthy men
14. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active-O-desmethyl metabolite
15. Venlafaxine oxidation in vitro is catalysed by CYP2D6
16. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency
17. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
18. Inhibitors of imipramine metabolism by human liver microsomes
19. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the anti-depressant agent venlafaxine in humans
20. Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine
21. Life-threatening hypotension from venlafaxine overdose
22. Block of sodium channels underlies unheralded cardiac toxicity observed with the antidepressant agent venlafaxine
23. 1 receptor antagonists
24. Classic antihistamines inhibit metoprolol hydroxylation in vitro
25. Diphenhydramine alters hemodynamic effects of metoprolol in man
26. Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs
27. Identification of diphenhydramine (Benadryl®) metabolites in human subjects
28. Identification of diphenhydramine urinary metabolites in the rhesus monkey
29. Metabolic disposition of diphenhydramine
30. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection
31. Salivary analysis for determination of dextromethorphan metabolic phenotype
32. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
33. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
34. 1795 in exon 3 generates a premature stop codon
35. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine
36. Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorometric detection
37. Sensitive high-performance liquid chromatography (HPLC) determination of diphenhydramine in plasma using fluorescence detection
38. Simultaneous analysis of diphenylmethoxyacetic acid, a metabolite of diphenhydramine, and its deuterium-labeled stable isotope analog in ovine plasma and urine
39. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
40. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration
41. Interindividual variations in drug disposition. Clinical implications and methods of investigation
42. 1-receptor antagonists. Comparative tolerability and safety
43. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes
44. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms
45. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
46. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver
47. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms